Connect to other sites within the UBM Medica Network
Results from a small study suggest that treatment with interferon alpha 2a could help chronic myeloid leukemia patients discontinue imatinib treatment. Image © molekuul.be / Shutterstock.com.
Interferon Could Help CML Patients Stop TKI Therapy
Results from a small study suggest that treatment with interferon alpha 2a could help chronic myeloid leukemia patients discontinue imatinib treatment.
Bosutinib a Good Fourth-Line Option in CML
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia found bosutinib to be a good option in the fourth-line setting.
Second-Gen TKIs Better in CML Patients With Elevated CIP2A Levels
CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.
Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment
A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.
RCC Drug Axitinib Could Treat TKI-Resistant CML
Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.
Omacetaxine Effective for Intolerant/Resistant CML
In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.
INTERIM Confirms 5-Year Efficacy of Intermittent Imatinib in CML
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.